Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about GH Research PLC
GH Research PLC News
Jun 20, 2025 - globenewswire.com
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
May 15, 2025 - globenewswire.com
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting
GH Research PLC Quantitative Score
About GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GH Research PLC Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
GH Research PLC Financials
Table Compare
Compare GHRS metrics with: | |||
|---|---|---|---|
Earnings & Growth | GHRS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GHRS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GHRS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GHRS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
GH Research PLC Income
GH Research PLC Balance Sheet
GH Research PLC Cash Flow
GH Research PLC Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
GH Research PLC Executives
| Name | Role |
|---|---|
| Ms. Julie Ryan F.C.A. | Vice President of Finance |
| Mr. Florian Schonharting M.Sc. (Econ) | Co-Founder & Non-Executive Chairman of the Board |
| Mr. Aaron Cameron M.B.A. | Chief Operating Officer |
| Mr. Magnus Halle | Co-Founder & MD of Ireland |
| Dr. Velichka Valcheva M.D., M.Sc. | Chief Executive Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Julie Ryan F.C.A. | Vice President of Finance | Female | 1987 | -- |
| Mr. Florian Schonharting M.Sc. (Econ) | Co-Founder & Non-Executive Chairman of the Board | Male | 1969 | -- |
| Mr. Aaron Cameron M.B.A. | Chief Operating Officer | Male | 1986 | -- |
| Mr. Magnus Halle | Co-Founder & MD of Ireland | Male | 1998 | -- |
| Dr. Velichka Valcheva M.D., M.Sc. | Chief Executive Officer | 1976 | -- |